共 50 条
- [1] IMPACT OF UP TO 6 MONTHS OF MEPOLIZUMAB TREATMENT FOR ADOLESCENTS AND ADULTS WITH EOSINOPHILIC ESOPHAGITIS IN THE SECOND PHASE OF A MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED CLINICAL TRIALGASTROENTEROLOGY, 2023, 164 (06) : S89 - S89Dellon, Evan S.Peterson, Kathryn A.Mitlyng, Benjamin L.Iuga, AlinaBookhout, Christine E.Cortright, Lindsay M.Walker, Kacie B.Gee, Timothy S.Cameron, Brenderia A.Galanko, JosephWoosley, John T.Eluri, SwathiMoist, Susan E.Hirano, Ikuo
- [2] Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trialGUT, 2023, 72 (10) : 1828 - 1837Dellon, Evan S.Peterson, Kathryn A.Mitlyng, Benjamin L.Iuga, AlinaBookhout, Christine E.Cortright, Lindsay M.Walker, Kacie B.Gee, Timothy S.McGee, Sarah J.Cameron, Brenderia A.Galanko, Joseph A.Woosley, John T.Eluri, SwathiMoist, Susan E.Hirano, Ikuo
- [3] A Randomized Placebo-Controlled Trial of Swallowed Fluticasone as Treatment of Eosinophilic EsophagitisAMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S21 - S22Alexander, JeffreyJung, Kee WookArora, AmindraEnders, FelicityFrancis, DawnKita, HirohitoRomero, YvonneKatzka, DavidSmyrk, ThomasTalley, Nicholas
- [4] A Randomized Placebo-Controlled Trial of Montelukast in Maintenance Treatment of Eosinophilic EsophagitisGASTROENTEROLOGY, 2016, 150 (04) : S19 - S19Alexander, Jeffrey A.Karthik, RaviEnders, FelicityGeno, Debra M.Kryzer, LoriMara, KristinSmyrk, ThomasKatzka, David A.
- [5] MEPOLIZUMAB IMPROVES HISTOLOGIC SEVERITY AS MEASURED BY THE EOE-HSS IN ADOLESCENS AND ADULTS WITH EOSINOPHILIC ESOPHAGITIS IN A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALGASTROENTEROLOGY, 2024, 166 (05) : S417 - S417Maniaci, JosephIuga, AlinaBookhout, Christine E.Cortright, Lindsay M.Walker, Kacie B.Moist, Susan E.Peterson, Kathryn A.Mitlyng, Benjamin L.Hirano, IkuoDellon, Evan S.
- [6] Mepolizumab For The Treatment Of Patients With Eosinophilic Granulomatosis With Polyangiitis: A Phase Iii Randomized, Placebo-Controlled TrialAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195Wechsler, M. E.Akuthota, P.Jayne, D.Khoury, P.Klion, A.Langford, C.Merkel, P. A.Moosig, F.Specks, U.Cid, M. C.Luqmani, R.Brown, J.Mallett, S.Philipson, R.Yancey, S.Steinfeld, J.Weller, P. F.Gleich, G.
- [7] Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic Esophagitis in adults: A randomized, placebo-controlled double-blind trialJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S44 - S44Straumann, A.Conus, S.Kita, H.Kephart, G.Bussmann, C.Beglinger, C.Patel, J.Byrne, M.Simon, H. U.
- [8] Budesonide As Induction Treatment For Active Eosinophilic Esophagitis In Adolescents And Adults: A Randomized, Double-blind, Placebo-controlled StudyJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S267 - S268Straumann, A.Degen, L.Felder, S.Bussmann, C.Conus, S.Thalmann, C.Simon, H.
- [9] Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis in Adolescents and Adults: Results From a Phase 3, Randomized, Placebo-Controlled TrialAMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S205 - S206Hirano, IkuoCollins, Margaret H.Katzka, David A.Mukkada, Vincent A.Falk, Gary W.Williams, JamesDesai, Nirav K.Lan, LanMorey, RobinDellon, Evan S.
- [10] Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trialJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : 456 - U275Spergel, Jonathan M.Rothenberg, Marc E.Collins, Margaret H.Furuta, Glenn T.Markowitz, Jonathan E.Fuchs, George, IIIO'Gorman, Molly A.Abonia, Juan PabloYoung, JamesHenkel, TimothyWilkins, H. JeffreyLiacouras, Chris A.